Aktienanalyse zu Mainz Biomed NV (MYNZ)

$0.844

+0.017 (+2.07%)Zum Schluss

Loading chart…

High: 0.861
Open: 0.803
VWAP: 0.81
Vol: 5.25M
Mkt Cap: 10.20M
Low: 0.739
Amount: 4.28M
EV/EBITDA, TTM: 0.00

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

www.mainzbiomed.com

AI analysis of Mainz Biomed NV (MYNZ)

hold

Mainz Biomed NV (MYNZ) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive trading signals, has no significant news or catalysts, and faces uncertainties due to a shift in business strategy and dilution concerns. It is better to hold off on investing in this stock at this time.

Bewertungskennzahlen

The current forward P/E ratio for Mainz Biomed NV (MYNZ) is -0.55, compared to its 5-year average forward P/E of -2.52.

Forward P/E

Fair

5Y Average P/E

-2.52

Current P/E

-0.55

Überbewertet

0.10

Unterbewertet

-5.13

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Überbewertet

0.00

Unterbewertet

0.00

Forward P/S

Fair

5Y Average P/S

54.54

Current P/S

10.62

Überbewertet

133.95

Unterbewertet

-24.87

Event-Zeitleiste

2026-03-13 (ET)